BACKGROUND Transcatheter left atrial appendage (LAA) ligation may represent an alternative to oral anticoagulation for stroke prevention in atrial fibrillation.
A trial fibrillation is a major risk factor for stroke and systemic embolism (1) . The primary source of thromboembolism in atrial fibrillation appears to be the left atrial appendage (LAA) (2) . Oral anticoagulation with vitamin K antagonists (VKAs) reduces thromboembolic risk and is recommended for stroke prevention in patients who are not at very low risk according to standardized risk scores (1) . Novel oral anticoagulant agents are noninferior and in some cases superior to VKA for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (3) (4) (5) (6) . However, both VKAs and the novel oral anticoagulant agents increase the risk of major bleeding, particularly from a gastrointestinal source, and are not suitable in a large proportion of patients because of prohibitive bleeding risk or other clinical reasons (7, 8) . Therefore, there exists a substantial clinical need for alternative approaches to stroke prevention in atrial fibrillation. A randomized clinical trial demonstrated that the efficacy of transcatheter occlusion of the LAA with a nitinol-based device and subsequent discontinuation of oral anticoagulation was noninferior to VKA (9) , and terminal therapy analysis of this trial further supported the contention that LAA closure is an effective alternative to systemic anticoagulation (10) . However, a permanent implant has several potential limitations, including device embolism, thrombus formation, erosion, and infection (9, (11) (12) (13) . These issues may be mitigated by an "implant-free" approach to LAA obliteration.
The Lariat device (SentreHeart, Redwood City, California) allows for the percutaneous ligation of the LAA through the delivery of a surgical suture via a combined transseptal and subxiphoid approach (14) .
This device has received a section 510(k) clearance from the U.S. Food and Drug Administration for the approximation of soft tissue and has been applied to LAA ligation in approximately 2,000 patients in the United States, according to the device manufacturer.
To date, the safety and efficacy of this approach have been explored in a few small, single-center studies that enrolled patients predominantly outside the United States. The objectives of this multicenter registry were to determine the clinical characteristics and post-procedure management of patients undergoing Lariat LAA ligation in current practice within the United States and to determine the safety and early efficacy of the procedure. TRANSCATHETER LAA LIGATION. The Lariat procedure has previously been described in detail (14) . In 
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PATIENT POPULATION. A total of 154 patients were enrolled at 8 sites (Appendix). A median of 19 patients (range 5 to 35 patients) were enrolled at each site. The average age was 72.1 AE 9.4 years; 38% of patients were female, 36% had diabetes mellitus, and 14% had a prior hemorrhagic stroke. The median CHADS 2 score was 3 (IQR: 2 to 4), the median CHA 2 DS 2 VASC score was 4 (IQR: 3 to 5), and the median HAS-BLED score was 3 (IQR: 2 to 4) ( Table 1) .
Before the procedure, 92 patients (60%) were being treated with an oral anticoagulant, 43 patients (28%) were on antiplatelet therapy alone, and 19 patients (12%) were on no anticoagulant or antiplatelet agent. PROCEDURAL CHARACTERISTICS. The average procedure duration was 76.6 AE 2.6 min. In 9 cases, the suture could not be delivered for the following reasons: pericardial adhesions preventing either pericardial sheath placement (2 cases) or limiting advancement of the epicardial wire or snare (3 cases); inability to advance the Lariat snare over the LAA due to challenging anatomy (2 cases); and emergency Among the 145 cases in which the suture was delivered, TEE demonstrated complete LAA closure at the end of the procedure in 133 (92%) and a residual leak <5 mm in 11 cases (7%) and $5 mm in 1 case. Device success (delivery of suture and residual leak <5 mm) was therefore achieved in 144 cases (94%).
PROCEDURAL COMPLICATIONS AND IN-HOSPITAL
OUTCOMES. There were a total of 15 patients (10%) with at least 1 major periprocedural complication (death, MI, stroke, major bleed, or emergent cardiac surgery). Major bleeding occurred in 14 patients (9%), driven by the need for transfusion ( Table 2) .
Emergency surgery was required in a total of 3 patients (2%), 2 for right ventricular perforation during pericardial access with subsequent cardiac tamponade and 1 for repair of LAA perforation. One patient died in the hospital 19 days post-procedure of respiratory failure, sepsis, and subsequent nosocomial pneumonia. There were no in-hospital strokes or MIs.
Overall, procedural success was achieved in 132 patients (86%) ( Table 3) . Anticoagulant and/or antiplatelet therapy at discharge was heterogeneous ( Table 4 ). The most frequent treatment at discharge was aspirin mono- Lariat unable to be deployed 9 (48) Pericardial adhesions 5
LAA anatomy 2
Aborted procedure after RV perforation 2
Residual Leak $ 5 mm 1 (6) Major complication before discharge 15 (71) Values are n or n (%). In 2 patients with procedural failure, there was both a major complication and the lariat was not deployed. In 1 patient, there was both a residual leak $ 5 mm and a major complication.
LAA ¼ left atrial appendage; RV ¼ right ventricular. Medical therapy at discharge after the Lariat procedure was heterogeneous. In addition to our experience, several cases of LAA thrombus after the Lariat procedure have been reported (25, 26) .
Although our study has insufficient power to iden- Consortium for Transcatheter LAA Ligation
